Mark Esq - Halozyme Therapeutics Senior Officer
| HALO Stock | USD 48.47 0.68 1.42% |
Executive
Mark Esq is Senior Officer of Halozyme Therapeutics
| Address | 12390 El Camino Real, San Diego, CA, United States, 92130 |
| Phone | 858 794 8889 |
| Web | https://halozyme.com |
Halozyme Therapeutics Management Efficiency
The company has return on total asset (ROA) of 0.1487 % which means that it generated a profit of $0.1487 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 1.1183 %, meaning that it created $1.1183 on every $100 dollars invested by stockholders. Halozyme Therapeutics' management efficiency ratios could be used to measure how well Halozyme Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 29th of November 2024, Return On Tangible Assets is likely to grow to 0.35. Also, Return On Capital Employed is likely to grow to 0.22. At this time, Halozyme Therapeutics' Return On Tangible Assets are very stable compared to the past year. As of the 29th of November 2024, Fixed Asset Turnover is likely to grow to 16.71, while Non Currrent Assets Other are likely to drop about 9 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| John Moore | Edgewise Therapeutics | 60 | |
| Scott Jordan | Cytokinetics | N/A | |
| Doug Wallace | Legend Biotech Corp | N/A | |
| Jennifer JD | Viridian Therapeutics | 52 | |
| Josep Garcia | Inhibrx | N/A | |
| Mandy Fahey | Insmed Inc | N/A | |
| Richard Shames | Protagonist Therapeutics | 64 | |
| Karen Lewis | Apellis Pharmaceuticals | 51 | |
| Yang Ji | BeiGene | N/A | |
| Kevin Eggan | Biomarin Pharmaceutical | N/A | |
| MD FCCP | Insmed Inc | 59 | |
| Amy Wireman | Biomarin Pharmaceutical | N/A | |
| Asif Ali | Protagonist Therapeutics | 50 | |
| Kevin MD | Insmed Inc | N/A | |
| Joanne Choi | Legend Biotech Corp | N/A | |
| Charbel PharmD | Inhibrx | N/A | |
| Ganesh Vedantham | Biomarin Pharmaceutical | N/A | |
| Nicole MBA | Insmed Inc | 56 | |
| Kathryn Haviland | Blueprint Medicines Corp | 48 | |
| Steven JD | Cytokinetics | 65 | |
| David MBA | Inhibrx | N/A | |
Management Performance
| Return On Equity | 1.12 | ||||
| Return On Asset | 0.15 |
Halozyme Therapeutics Leadership Team
Elected by the shareholders, the Halozyme Therapeutics' board of directors comprises two types of representatives: Halozyme Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Halozyme. The board's role is to monitor Halozyme Therapeutics' management team and ensure that shareholders' interests are well served. Halozyme Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Halozyme Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mark Esq, Senior Officer | ||
| Kristin Schwartzbauer, Head Quality | ||
| Gary Grote, Chief Officer | ||
| Nicole LaBrosse, CFO Director | ||
| MD MBA, Chief Officer | ||
| Nicole CPA, Senior CFO | ||
| Amy Fox, Senior Resources | ||
| Cortney MBA, Chief Officer | ||
| Michael LaBarre, Senior Officer | ||
| Steve MBBS, Chief Officer | ||
| Todd Butler, VP CEO | ||
| Christopher Bryant, Chief Operations | ||
| MRCP B, CEO President | ||
| Tram Bui, Head Communications |
Halozyme Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Halozyme Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 1.12 | ||||
| Return On Asset | 0.15 | ||||
| Profit Margin | 0.41 % | ||||
| Operating Margin | 0.56 % | ||||
| Current Valuation | 7 B | ||||
| Shares Outstanding | 127.23 M | ||||
| Shares Owned By Insiders | 1.07 % | ||||
| Shares Owned By Institutions | 98.93 % | ||||
| Number Of Shares Shorted | 10.45 M | ||||
| Price To Earning | 60.08 X |
Pair Trading with Halozyme Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Halozyme Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Halozyme Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Halozyme Stock
| 0.64 | ELAN | Elanco Animal Health Potential Growth | PairCorr |
Moving against Halozyme Stock
| 0.6 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.59 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.58 | ESPR | Esperion Therapeutics | PairCorr |
| 0.47 | GANX | Gain Therapeutics | PairCorr |
| 0.44 | GILD | Gilead Sciences | PairCorr |
The ability to find closely correlated positions to Halozyme Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Halozyme Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Halozyme Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Halozyme Therapeutics to buy it.
The correlation of Halozyme Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Halozyme Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Halozyme Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Halozyme Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Halozyme Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Halozyme Stock, please use our How to Invest in Halozyme Therapeutics guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Halozyme Therapeutics. If investors know Halozyme will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Halozyme Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.721 | Earnings Share 3.02 | Revenue Per Share 7.431 | Quarterly Revenue Growth 0.343 | Return On Assets 0.1487 |
The market value of Halozyme Therapeutics is measured differently than its book value, which is the value of Halozyme that is recorded on the company's balance sheet. Investors also form their own opinion of Halozyme Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Halozyme Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Halozyme Therapeutics' market value can be influenced by many factors that don't directly affect Halozyme Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Halozyme Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Halozyme Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Halozyme Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.